https://www.selleckchem.com/pr....oducts/i-brd9-gsk602
With this change in dialysis regimen, patient was able to continue treatment with sunitinib. Clinicians prescribing sunitinib should be vigilant to monitor for this complication in patients receiving sunitinib, apart from the more usual presentation of hepatotoxicity. We found that a more intensive hemodialysis regimen consisting of 4× a week conventional high-flux hemodialysis (HD) can permit the continuation of treatment with sunitinib in an end stage renal disease (ESRD) patient with Child-Pugh class B liver cirrhosis. Clinicia
Like
Comment
Share
